ELI LILLY AND COMPANY Other Payments to Acquire Businesses
ELI LILLY AND COMPANY (LLY) reported Other Payments to Acquire Businesses of $9.80 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:OtherPaymentsToAcquireBusinesses · last filed 2026-08-05
- ELI LILLY AND COMPANY other payments to acquire businesses for the quarter ending 2026-06-30 was $8.75B.
- ELI LILLY AND COMPANY other payments to acquire businesses for the quarter ending 2026-03-31 was $1.06B.
- ELI LILLY AND COMPANY other payments to acquire businesses for the quarter ending 2025-12-31 was $111.60M, a 37100.00% increase year-over-year.
- ELI LILLY AND COMPANY other payments to acquire businesses for the quarter ending 2025-09-30 was $549.40M.
- ELI LILLY AND COMPANY other payments to acquire businesses for fiscal 2025 was $661.00M, a 30.27% decline from fiscal 2024.
- ELI LILLY AND COMPANY other payments to acquire businesses for fiscal 2024 was $948.00M, a 9.20% decline from fiscal 2023.
- ELI LILLY AND COMPANY other payments to acquire businesses for fiscal 2023 was $1.04B, a 219.07% increase from fiscal 2022.
- ELI LILLY AND COMPANY other payments to acquire businesses for fiscal 2022 was $327.20M, a 56.22% decline from fiscal 2021.
| Period end | Other Payments to Acquire Businesses 3 month | Other Payments to Acquire Businesses 6 month | Other Payments to Acquire Businesses 9 month | Other Payments to Acquire Businesses 12 month | Other Payments to Acquire Businesses 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.75B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $9.80B 10-Q · filed 2026-08-05 | $9.92B derived: sum of 3 quarters · filed 2026-08-05 | $10.47B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $1.06B 10-Q · filed 2026-04-30 | $1.17B derived: sum of 2 quarters · filed 2026-04-30 | $1.72B derived: sum of 3 quarters · filed 2026-04-30 | $1.72B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $111.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $661.00M derived: sum of 2 quarters · filed 2026-02-12 | $661.00M derived: sum of 3 quarters · filed 2026-08-05 | $661.00M 10-K · filed 2026-02-12 | |
| 2025-09-30 | $549.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $549.40M derived: sum of 2 quarters · filed 2026-08-05 | $549.40M 10-Q · filed 2025-10-30 | $549.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $300.00K derived: sum of 3 quarters · filed 2026-08-05 | $300.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $300.00K derived: sum of 2 quarters · filed 2026-04-30 | $300.00K derived: sum of 3 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $300.00K derived: sum of 2 quarters · filed 2026-02-12 | $948.00M 10-K · filed 2026-02-12 | $947.70M 10-K · filed 2025-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $947.70M 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | $947.70M 10-Q · filed 2025-08-07 | ||||
| 2023-12-31 | $1.04B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.04B derived: sum of 2 quarters · filed 2026-02-12 | $1.04B 10-K · filed 2026-02-12 | $1.04B 10-K · filed 2024-02-21 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | ||||
| 2022-12-31 | $327.20M 10-K · filed 2025-02-19 | ||||
| 2021-12-31 | $747.40M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |